Albuminuria: An Overlooked Red Flag in Cardiovascular Risk
Conversations in CV Risk AssessmentAlbuminuria: An Overlooked Red Flag in Cardiovascular Risk
Uncovering Cardiovascular Risk in Patients with Target Blood Pressure
Conversations in CV Risk AssessmentUncovering Cardiovascular Risk in Patients with Target Blood Pressure
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart MattersRethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- advertisement
- 3 questions
- advertisement
Rethinking Diabetes Care: Key Data from Incorporating Lifestyle Modifications
Medical Industry FeatureRethinking Diabetes Care: Key Data from Incorporating Lifestyle Modifications
- 12/19/2025
- 12/18/2025
- 12/18/2025
- 12/18/2025
- 12/16/2025
- 12/15/2025